Pharmacoeconomics of ivabradine in the treatment of CHF in the context of"Quadruple Therapy"
OBJECTIVE To evaluate the cost-effectiveness of ivabradine in the treatment of chronic heart failure(CHF)in the context of"Quadruple Therapy"from the perspective of the health system.METHODS Based on real-world cohort data,the Markov model was constructed according to the natural progression of CHF,with a cycle time of 3 months,a study timeframe of 20 years,and a discount rate of 5%.Using quality-adjusted life year(QALY)and incremental cost-effectiveness ratios(ICER)as the output indexes,the cost-utility analysis was used to evaluate the cost-effectiveness of ivabradine in combination with the"Quadruple Therapy"regimen,compared with the"Quadruple Therapy"regimen for the treatment of CHF,and the robustness of the results of the base analysis was verified by univariate sensitivity analysis and probabilistic sensitivity analysis.RESULTS The results of the base analysis showed that the ICER of ivabradine combined with the"Quadruple Therapy"regimen was 165 065.54 yuan/QALY,compared with the"Quadruple Therapy"regimen,which was lower than the willingness-to-pay(WTP)threshold(257 094 yuan/QALY)based on 3 times of China's gross domestic product(GDP)per capita in 2022.The results of the univariate sensitivity analysis showed that the discount rate had the greatest impact on the robustness of the model.The probabilistic sensitivity analysis showed that the probability that the ivabradine combined with the"Quadruple Therapy"regimen was cost-effective under the WTP threshold in this study was 59.50%.CONCLUSIONS When using 3 times China's 2022 GDP per capita(257 094 yuan/QALY)as the WTP threshold,the combination of ivabradine and the"Quadruple Therapy"regimen for treating CHF is cost-effective.
国家科技期刊平台
NSTL
万方数据
